The Epigenetics Healthcare R&D, Products and Commercial Implications

Tools, Technologies, Equipment, Opportunities & Emerging WW Market Outlook

Product Code FUJ00067
Publication Date January 2009
Publisher Fuji-Keizai
Product Type Report
Pages 148
ISBN Number not applicable
Change currency
PDF £1,450.00 €1,746 $2,293 BUY >
PRINT £945 €1,138 $1,494 BUY >
Order by fax
Ask a question about this product > Receive product alerts > Call now +44 20 7060 7474

The Epigenetics Healthcare R&D, Products and Commercial Implications

Tools, Technologies, Equipment, Opportunities & Emerging WW Market Outlook

This report presents information about the quickly emerging worldwide epigenetics market. This important life science market includes key product areas that will have a powerful impact on current and future healthcare. This broad and high-level report takes a business focus and analyzes epigenetics markets such life science tools and technologies, diagnostics and therapeutics

We all know about the human genome and our DNA. Its special code defines the structure of who we are, our potential health and our characteristics that we pass on to our children. Epigenetics represents the second code of life that signals to the DNA whether and when genes are activated or silenced. The genome is like the musical instrument; the epigenome is like the music.

The study discusses the market for life science tools and technologies that enable epigenetics R&D. The report discusses key equipment and consumables including microarray, next-generation sequencing, PCR and other platforms. Topics such as microRNA and human stem cells are lightly covered. The report highlights some of main government grant initiatives such as the NIH's Roadmap Epigenomics Program initiatives, the EU's Epigenetic Network of Excellence and others. The research covers subjects including important epigenetic factors including DNA methylation, histone modifications and other potential biomarkers.

The report discusses epigenetic commercial diagnostics and therapeutics that will foster personalized medicine. This research examines the current epigenetic therapeutics on the market and the drugs in the clinical pipeline.

This study discusses the interesting topics with key findings. The data estimates that the worldwide epigenetics product market will reach $1.7 billion in 2009, with a growth rate. The report reviews the activities of 35 companies. This report uses 39 figures and tables to illustrate the findings. This study features many convenient tables that help the reader scan the details of key trends, market segmentation, forecast, M&As, alliances, grant funding, patents and the like.

Contents

  • 1. Overview of the Epigenetics Market and R&D
    • 1.1 Overview of Epigenetics for R&D, Diagnostics & Therapeutics
      • 1.1.2 Definition and Brief History of Epigenetics
      • 1.1.3 Epigenetic Mechanisms in Human Health
      • 1.1.4 Cancers, Neuropsychological Conditions or Other Diseases and Demographics Involving Epigenetics
      • 1.1.5 Tools, Technologies, Equipment & Products for Epigenetic R&D
      • 1.1.6 Diagnostics for Epigenetic Conditions
      • 1.1.7 Therapeutics for Epigenetic Diseases
    • 1.2 Epigenetics Applications
      • 1.2.1 Academic Life Science Research Applications
      • 1.2.2 Clinical Diagnostic Applications
      • 1.2.3 Pharma/ Biotech Therapeutic Applications
  • 2. Major Alliances, M&As and IP
    • 2.1 Summary of Key Alliances and M&As Involving Epigenetics
      • 2.1.1 Definitions of Alliance and M&A Deal Types
      • 2.1.2 Highlights of Major Alliances and M&As Involving Epigenetics
      • 2.1.3 Data Tables for Alliances and M&As, 2005 Oct. 2008
    • 2.2 Patents, Business Development and Challenges
      • 2.2.1 Highlights of Companies That Own IP Involving Epigenetic Techs.
      • 2.2.2 The Business Value of Epigenetic Technologies and Products
      • 2.2.3 Business Development Challenges
      • 2.2.4 Patent Challenges
  • 3. 3The Market and Outlook for the Epigenetics Industry
    • 3.1 The Total Epigenetics Market Size, 2008~2013
    • 3.2 Epigenetic Market by Product Segments
      • 3.2.2 Epigenetic Life Science R&D Tools and Technologies Segment and Sub-segments 48
      • 3.2.3 Epigenetic Diagnostics Segment and Sub-segments
      • 3.2.4 Epigenetic Therapeutics Segment and Sub-segments
      • 3.2.5 WW Epigenetic Market By Product Segment Shares, 2008 & 2013
    • 3.3 Market by Leading Diseases
      • 3.3.2 Cancer Disease Segment
      • 3.3.3 Neuro-psychological (CNS) Segment
      • 3.3.4 Infections Disease Segment
      • 3.3.5 Respiratory Disease Segment
      • 3.3.6 Reproductive Disease Segment
      • 3.3.7 Others Disease Segment
    • 3.4 Epigenetic Market by R&D Developer Segments
      • 3.4.2 Academic/Gov. Basic Life Science Developer Sub-segments
      • 3.4.3 Diagnostics Developer Sub-segments
      • 3.4.4 Pharma/ Biotech Rx/Tx Developers Sub-segments
    • 3.5 Market by WW Regions
      • 3.5.2 North America
      • 3.5.3 Europe
      • 3.5.4 Japan
      • 3.5.5 ROW
  • 4. Activities of Epigenetic Product Developers
    • 4.1 Epigenetic Diagnostics Developers
      • 4.1.1~ 4.1.5 Total 5 companies
    • 4.2 Equipment Systems Companies
      • 4.2.1~ 4.2.5 Total 5 companies
    • 4.3 Consumables, Reagents and Kits Companies
      • 4.3.1~ 4.3.10 Total 10 companies
    • 4.4 Contract R&D Services Companies
      • 4.4.1~ 4.4.7 Total 7 companies
    • 4.5 Life Science Software Companies
      • 4.5.1~ 4.5.5 Total 5 companies
  • 5. Conclusions and New Business Opportunities
    • 5.1 The Future of the Epigenetics Market
      • 5.1.1 Tools & Technologies for Genomewide Epigenetic R&D
        • 5.1.1.1 Commercial DNA Microarrays, ChIP on Chip and Methylation
        • 5.1.1.2 High-Throughput Sequencing and ChIP-Seq.
        • 5.1.1.3 Other Front Runner Technologies
      • 5.1.2 Consumables & Reagent Kits
      • 5.1.3 Commercial Diagnostic/ Test Services
      • 5.1.4 Therapeutics Involving Epigentics
    • 5.2 Likely Epigenetics Success and Failure Factors
      • 5.2.1 US Initiative - The NIH Roadmap Epigenomics Program Initiatives
      • 5.2.2 European Union Initiative - The European Union Epigenetics Initiative
      • 5.2.3 Key M&As Have Enabled Epigenetic Product Companies
      • 5.2.4 Commercial Epigenetic Diagnostics Have Reached the Market With More to Come
      • 5.2.5 Commercial Epigenetic Therapeutics Have Reached the Market
    • 5.3 Epigenetic Business Opportunities or Commercial Implications
      • 5.3.1 New Business Opportunities for American and European Companies
        • 5.3.1.1 Life Science Tools and Technologies
        • 5.3.1.2 Explore Other WW Regions for Cost Savings or New Customers
        • 5.3.1.3 Enter Asia for Business Opportunities
      • 5.3.2 New Business Opportunities for Japanese and Asian Companies
  • 6. Appendix
    • 6.1 Glossary of Epigenetics
    • 6.2 Company Contacts
    • 6.3 Grant Recipients and Epigenomic Projects
  • LIST OF TABLES
    • Table 1. Demographics of Epigenetic Related Diseases
    • Table 2. Summary of Key Alliances and M&As, 2005 to Oct.- 2008
    • Table 3. Major Alliances and M&As Jan. to Oct. 2008
    • Table 4. Major Alliances and M&As - 2007
    • Table 5. Major Alliances and M&As - 2006
    • Table 6. Major Alliances and M&As - 2005
    • Table 7. Epigenetics Related US Patents Issued to Orgs., 2007 to Oct.- 2008
    • Table 8. Valuations of Major M&As Involving Epigenetics.
    • Table 9. Total WW Epigenetic Product Market Revenues, 2008-2013
    • Table 10. WW Epigenetic Market By Vendor Product Segments $M
    • Table 11. Epigenetic Life Science R&D Tools & Technologies Sub-segments $M
    • Table 12. Epigenetic Diagnostics Sub-segments $M
    • Table 13. Epigenetic Therapeutics Sub-segments $M
    • Table 14. WW Epigenetic Market By Vendor Product Shares %, 2008 & 2013
    • Table 15. WW Epigenetic Market By Leading Diseases $M
    • Table 16. Major Cancer Types Targeted in R&D and Shares
    • Table 17. WW Epigenetic Market By Developers $M
    • Table 18. Academic/Gov. Basic Life Science R&D $M
    • Table 19. Diagnostics Developers
    • Table 20. Pharma/ Biotech Rx/Tx Developers
    • Table 21. WW Epigenetic Market By Regions $M
    • Table 22. High-Density Whole Genome Microarrays for Epigenetics
    • Table 23. High-Throughput DNA Sequencing For Epigenetics
    • Table 24. Other Technologies for Epigenetics
    • Table 25. Epigenetic Diagnostics Development Pipeline
    • Table 26. Therapeutics in Clinical Pipeline Involving Epigenetics
    • Table 27. NIH Roadmap Epigenomics Program Initiatives
    • Table 28. Glossary of Epigenetic Terms
    • Table 29. List of Company Contacts
    • Table 30. Selected NIH Grant Recipients and Epigenomic Projects
  • LIST OF FIGURES
    • Figure 1. The Epigenetic Product Market Ecosystem
    • Figure 2. Highlights of Epigenetic Mechanisms
    • Figure 3. Increasing Number of PubMed Articles Regarding Epigenetics
    • Figure 4. Total WW Epigenetic Product Market Revenues, 2008-2013
    • Figure 5. WW Epigenetic Market By Vendor Products $M
    • Figure 6. WW Epigenetic Market By Vendor Product Shares %, 2008 & 2013
    • Figure 7. WW Epigenetic Market By Leading Diseases $M
    • Figure 8. WW Epigenetic Market By Developers $M
    • Figure 9. WW Epigenetic Market By Regions $M